

NOTICE OF MATERIAL CHANGE TO CONTRACT



July 1, 2021

Re: Site-of-Care medical necessity reviews for long-acting colony-stimulating factors will not be implemented on August 1, 2021

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Colorado (Anthem), is providing an update to our letter dated March 1, 2021, regarding Site-of-Care medical necessity reviews for long-acting colony-stimulating factors.

The program will not be implemented on August 1, 2021. Medical necessity review of the site-of-care following long acting colony-stimulating factors for oncology indications will not be required beginning August 1, 2021, as originally communicated.

- Neulasta® & Neulasta Onpro® (pegfilgrastim)
- Fulphila® (pegfilgrastim-jmdb)
- Udenyca® (pegfilgrastim-cbqv)
- Ziextenzo® (pegfilgrastim-bmez)
- Nyvepria™ (pegfilgrastim-apgf)

There will be no changes for ordering providers whom submit prior authorization requests for the hospital outpatient site-of-care for these medications for dates of service on or after August 1, 2021. Providers should continue to verify eligibility and benefits for all members prior to rendering services.

Note: In some plans “level of care” or another term such as “setting” or “place of service” may be the term used in benefit plans, provider contracts or other materials instead of or in addition to “site-of-care” and in some plans, these terms may be used interchangeably. For simplicity, we will hereafter use “site-of-care.”

We value and appreciate you as our partner in providing quality care and appreciate your continued participation in our network. If you have questions, please call the Provider Service phone number on the member’s ID card.

Sincerely,

A handwritten signature in black ink, appearing to read "Jonathan Sollender".

Jonathan Sollender, MD, MBA, FACS
Regional Vice President and Senior Clinical Officer
Commercial & Specialty Business Division